Breast cancer is considered a heterogeneous group of diseases at the molecular level, whose comprehensive care regimen depends on the molecular subtype of each individual patient, and approximately 70% of all breast cancer cases are hormone receptor (HR)‐positive [3, 4]. The gene discussed is NR4A1; the disease is breast carcinoma.